GO:0046579 positive regulation of Ras protein signal transduction: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046579 describes any process that activates or increases the frequency, rate or extent of Ras protein signal transduction, a central signaling node controlling cell proliferation, differentiation and survival.
• The term is a biological process annotation that sits downstream of receptor tyrosine kinase activation and upstream of the RAF-MEK-ERK and PI3K-AKT effector cascades.
• Loss-of-function or dominant-negative mutations in regulators such as LZTR1 enhance RAS-MAPK signaling and cause Noonan syndrome, demonstrating that positive regulation of Ras signaling is dosage-sensitive in human disease.
• KRAS mutation subtypes cooperate with other driver mutations to reshape oncogenic pathway output, making positive regulation of Ras signaling a context-dependent therapeutic target.
• Experimental dissection of GO:0046579 requires perturbation of candidate regulators using CRISPR knockout, point-mutation knock-in or overexpression models combined with phospho-ERK readouts and transcriptomic profiling.
• Emerging work shows that positive regulation of Ras signaling can be modulated by non-coding mechanisms, including exosomal miRNAs and metabolic rewiring, expanding the set of druggable nodes in this pathway.
Description
GO:0046579, positive regulation of Ras protein signal transduction, is a Gene Ontology biological process term that captures any molecular event which activates or increases the frequency, rate or extent of signaling through Ras-family small GTPases. Ras proteins act as binary molecular switches that cycle between an inactive GDP-bound state and an active GTP-bound state, and the positive regulation of this cycle is essential for transmitting extracellular growth signals to intracellular effector pathways. Because Ras signaling is one of the most frequently dysregulated pathways in human cancer and in developmental disorders, understanding which genes and mechanisms positively regulate it is a central question in biomedical research. The term is deliberately broad: it includes guanine nucleotide exchange factors that promote GTP loading, adaptor proteins that recruit Ras to activated receptors, post-translational modifications that favor membrane localization, and feedback loops that sustain active Ras. It also encompasses indirect regulators, such as ubiquitin ligases and metabolic enzymes, whose perturbation alters the amplitude or duration of Ras-MAPK output. This breadth makes GO:0046579 a useful annotation for interpreting genome-wide screens and for prioritizing candidate genes in disease contexts. For researchers, GO:0046579 provides a shared vocabulary to describe experiments that measure changes in Ras pathway activity, whether by phospho-ERK immunoblotting, RAS-GTP pulldown, or transcriptional reporters. The sections below summarize the definition, the major genes and mechanisms, disease links, and the CRISPR-based methods used to study positive regulation of Ras protein signal transduction.
positive regulation of Ras protein signal transduction At A Glance
| GO ID | GO:0046579 |
|---|---|
| GO term | positive regulation of Ras protein signal transduction |
| Ontology | biological_process |
| Definition | Any process that activates or increases the frequency, rate or extent of Ras protein signal transduction. |
| Synonym | activation of Ras protein signal transduction; stimulation of Ras protein signal transduction; up regulation of Ras protein signal transduction; up-regulation of Ras protein signal transduction; upregulation of Ras protein signal transduction |
| Major function | Enhances the amplitude, duration or frequency of Ras GTPase signaling to downstream effectors such as RAF-MEK-ERK and PI3K-AKT. |
| Upstream inputs | Activated receptor tyrosine kinases, adaptor proteins, guanine nucleotide exchange factors and post-translational modifiers. |
| Downstream outputs | Phosphorylation of ERK1/2, transcriptional activation of immediate early genes, and metabolic or immune reprogramming. |
| Disease relevance | Somatic KRAS mutations in cancer and germline LZTR1 mutations in Noonan syndrome both converge on increased Ras signaling. |
What Is GO:0046579?
In plain terms, GO:0046579 refers to any biological process that switches Ras signaling on or turns it up. The official QuickGO definition states: Any process that activates or increases the frequency, rate or extent of Ras protein signal transduction. This includes events that promote the formation of active GTP-bound Ras, stabilize active Ras at the membrane, enhance coupling to downstream effectors such as RAF and PI3K, or sustain signaling through positive feedback loops. The term is a child of positive regulation of intracellular signal transduction and is annotated to gene products whose experimental perturbation increases Ras pathway output.
Why Is positive regulation of Ras protein signal transduction Important in Cell Biology?
Positive regulation of Ras protein signal transduction is important because the Ras-MAPK axis is one of the most frequently mutated and most therapeutically pursued pathways in human disease. Gain-of-function KRAS mutations are common in solid tumors, and even in tumors without direct Ras mutations, upstream positive regulators can amplify signaling to drive proliferation and immune evasion. In developmental disorders, dominant mutations in the Ras regulator LZTR1 increase RAS-MAPK signaling and cause Noonan syndrome, illustrating that the positive regulation arm of this pathway is dosage-sensitive. Consequently, identifying and validating genes annotated to GO:0046579 is essential for understanding oncogenesis, for interpreting cancer genomics, and for designing combination therapies that target pathway reactivation.
• KRAS mutation subtypes are among the most common oncogenic drivers, and their signaling output is shaped by co-occurring mutations in other pathways.
• Germline mutations in LZTR1 that impair its function lead to enhanced RAS-MAPK signaling and Noonan syndrome, directly linking positive regulation of Ras signaling to developmental disease.
• Positive regulation of Ras signaling supports immune evasion in KRAS-driven cancers, connecting this GO term to immunotherapy resistance.
• The pathway intersects with metabolic and autophagy regulation, as shown by USP13-dependent switching that requires KRAS signaling.
• Non-coding regulators such as exosomal miRNAs can modulate KRAS-MAPK signaling, expanding the scope of positive regulation beyond protein-coding genes.
• Feedback loops involving proteins such as RASH3D19 sustain RAS activation in KRAS-mutant cancer, highlighting the importance of positive feedback in pathway maintenance.
• Ras pathway activity is a key determinant of sensitivity to MEK and ERK inhibitors, making its positive regulators candidate biomarkers.
• CRISPR screens and functional genomics rely on GO:0046579 annotations to prioritize genes whose knockout reduces Ras pathway output.
• Understanding positive regulation of Ras signaling is prerequisite for designing combinatorial strategies that prevent adaptive resistance.
• The term provides a standardized framework for comparing experimental results across cell models and disease contexts.
What Happens During positive regulation of Ras protein signal transduction?
Receptor-proximal activation and adaptor recruitment
In simple terms: Growth factor receptors on the cell surface recruit adaptor proteins that bring Ras to the membrane and switch it on.
Positive regulation of Ras signaling begins when activated receptor tyrosine kinases phosphorylate adaptor proteins such as GRB2 and SHC, which in turn recruit guanine nucleotide exchange factors like SOS1 to the plasma membrane. This recruitment increases the local concentration of Ras in its active, GTP-bound state. Experimental evidence from LZTR1 studies shows that perturbation of adaptor-proximal regulation directly alters RAS-MAPK output, confirming that this step is a bona fide positive regulatory node.
Guanine nucleotide exchange and GTP loading
In simple terms: Exchange factors pry GDP out of Ras so that GTP can bind and turn the switch on.
Guanine nucleotide exchange factors catalyze the release of GDP from Ras, allowing the more abundant GTP to bind and stabilize the active conformation. This step is the canonical positive regulatory event for Ras proteins. In KRAS-mutant cancer, positive feedback loops can sustain GTP loading even after upstream receptor stimulation is removed, as demonstrated for RASH3D19-mediated RAS activation. The duration and amplitude of GTP loading determine downstream ERK phosphorylation kinetics.
Membrane anchoring and post-translational modification
In simple terms: Ras must be tethered to the membrane to work, and modifications like ubiquitination or lipidation control that tethering.
Ras proteins require C-terminal lipid modifications and membrane association for signaling. LZTR1 functions as a regulator of RAS ubiquitination, and its loss increases RAS abundance at the membrane and enhances signaling. Glycosphingolipid synthesis has also been shown to mediate immune evasion in KRAS-driven cancer, indicating that lipid metabolism intersects with positive regulation of Ras signaling. These findings place post-translational and metabolic modifications among the mechanisms that positively regulate Ras signal transduction.
Effector engagement and downstream cascade activation
In simple terms: Active Ras binds effector proteins that relay the signal to the nucleus and cytoplasm.
Once in the GTP-bound state, Ras engages effectors including RAF kinases, PI3K, and RALGDS, leading to activation of MEK-ERK, AKT-mTOR, and other cascades. Positive regulation of Ras signal transduction therefore manifests as increased phosphorylation of ERK1/2 and AKT, and as transcriptional changes in immediate early genes. Studies in KRAS-mutant models show that this effector engagement is required for phenotypes such as ferroptosis-to-autophagy switching and immune evasion.
Feedback amplification and pathway maintenance
In simple terms: Once switched on, the pathway can keep itself active through positive feedback loops.
Positive regulation of Ras signaling is not a one-way street; feedback loops can sustain pathway activity. RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer, illustrating how the pathway can maintain its own active state. Similarly, USP13-dependent activation of the NFE2L2/NRF2-SQSTM1/p62-KEAP1 axis requires KRAS signaling, showing that downstream modules can reinforce pathway output. These mechanisms are important for understanding resistance to single-agent inhibitors.
Key Genes Involved in GO:0046579 positive regulation of Ras protein signal transduction
The following genes and proteins are experimentally implicated in positive regulation of Ras protein signal transduction, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KRAS | Proto-oncogenic small GTPase; active when GTP-bound | Most frequently mutated Ras isoform in cancer; central to GO:0046579 |
| LZTR1 | Regulator of RAS ubiquitination and signaling; loss enhances RAS-MAPK | Germline mutations cause Noonan syndrome; key negative-to-positive switch |
| SOS1 | Guanine nucleotide exchange factor for Ras | Canonical positive regulator recruited by GRB2 |
| GRB2 | Adaptor protein linking activated receptors to SOS1 | Required for receptor-proximal Ras activation |
| SHC1 | Adaptor that recruits GRB2-SOS1 complexes | Contributes to growth factor-induced Ras activation |
| RAF1 | Serine/threonine kinase effector of active Ras | Downstream readout of positive regulation; disease relevance in RASopathies |
| MAP2K1 | MEK1 kinase downstream of RAF | Phospho-ERK readout for Ras pathway activity |
| MAPK1 | ERK2 kinase; terminal kinase of the cascade | Phospho-ERK is a standard marker of positive regulation |
| PIK3CA | Catalytic subunit of PI3K; effector of active Ras | Links Ras signaling to AKT-mTOR and metabolism |
| AKT1 | Serine/threonine kinase downstream of PI3K | Readout of Ras-PI3K crosstalk |
| NFE2L2 | NRF2 transcription factor; activated downstream of KRAS | Mediates ferroptosis-to-autophagy switch |
| SQSTM1 | p62 autophagy receptor; regulated by KRAS signaling | Links Ras pathway to autophagy and stress responses |
| USP13 | Deubiquitinase required for NRF2-p62-KEAP1 axis | Modulates Ras-dependent autophagy switch |
| RASH3D19 | RAS activation mediator via positive feedback | Sustains RAS activity in KRAS-mutant cancer |
| UBA1 | Ubiquitin-activating enzyme in RAS ubiquitination cascade | Cooperates with LZTR1 in RAS regulation |
| CUL3 | Cullin-RING ligase scaffold for LZTR1 complexes | Required for LZTR1-mediated RAS ubiquitination |
| SHP2 (PTPN11) | Protein tyrosine phosphatase that promotes Ras activation | RASopathy gene; positive regulator of Ras-MAPK |
| NF1 | GTPase-activating protein; loss increases active Ras | Neurofibromatosis type 1; negative regulator whose loss is positive regulation |
How Is positive regulation of Ras protein signal transduction Regulated?
Positive regulation of Ras protein signal transduction is itself subject to multiple layers of control. Ubiquitination and degradation of Ras by the LZTR1-CUL3 complex restricts the amount of Ras available for activation, so loss of LZTR1 function increases signaling. Phosphatases such as SHP2 (PTPN11) promote Ras activation by removing inhibitory phosphorylation marks on adaptor proteins, and their mutations are associated with RASopathies. Metabolic and stress-responsive pathways also feed in: glycosphingolipid synthesis supports immune evasion in KRAS-driven cancer, and USP13-dependent activation of the NRF2-p62-KEAP1 axis requires KRAS signaling. Finally, positive feedback loops such as those mediated by RASH3D19 can maintain RAS in an active state even when upstream inputs decline. Together, these mechanisms determine the set point of Ras pathway activity in normal and diseased cells.
positive regulation of Ras protein signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KRAS | Pancreatic, lung and colorectal cancer; immune evasion | KRAS G12D or G12V knock-in cell lines; KO of KRAS in mutant lines |
| LZTR1 | Noonan syndrome; enhanced RAS-MAPK signaling | Patient-derived LZTR1 point-mutation knock-in; KO for pathway activation |
| NF1 | Neurofibromatosis type 1; loss increases active Ras | NF1 knockout in Schwann cell or fibroblast models |
| PTPN11 | Noonan syndrome and LEOPARD syndrome | SHP2 point-mutation knock-in to mimic gain-of-function |
| USP13 | KRAS-dependent ferroptosis-to-autophagy switch | USP13 knockout with KRAS-mutant background |
Cancer: KRAS-driven malignancies
Somatic mutations in KRAS are among the most common oncogenic drivers, and their signaling output is influenced by co-occurring mutations in other pathways. Positive regulation of Ras signal transduction supports tumor cell proliferation, survival and immune evasion; for example, glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer. In rhabdomyosarcoma, genomic analysis revealed alterations affecting a common genetic axis, underscoring the breadth of Ras pathway involvement in solid tumors. Therapeutic strategies must therefore account for positive feedback and adaptive rewiring that sustain Ras signaling.
Developmental disorders: Noonan syndrome and RASopathies
Dominant Noonan syndrome-causing mutations in LZTR1 specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling. This demonstrates that impaired negative regulation of Ras, which is functionally equivalent to increased positive regulation, causes a defined developmental phenotype. LZTR1 is a regulator of RAS ubiquitination and signaling, and its dysfunction leads to accumulation of active Ras. These findings link GO:0046579 directly to human germline disease and provide a rationale for pathway-directed therapies in RASopathies.
Inflammatory and autoimmune conditions
Ginseng exosomal miRNA has been shown to ameliorate rheumatoid arthritis by mediating KRAS-MAPK signaling, indicating that positive regulation of Ras signaling participates in inflammatory disease. This suggests that modulating Ras pathway activity could have therapeutic potential beyond oncology, although the mechanisms remain under investigation.
Metabolic and autophagy-related pathology
USP13 facilitates a ferroptosis-to-autophagy switch by activation of the NFE2L2/NRF2-SQSTM1/p62-KEAP1 axis dependent on the KRAS signaling pathway. Because positive regulation of Ras signaling can determine whether cells undergo ferroptosis or autophagy, this pathway is relevant to metabolic stress responses and to the design of therapies that exploit these vulnerabilities.
From positive regulation of Ras protein signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase Ras pathway output? | CRISPR knockout in a cell line with measurable phospho-ERK |
| Does a specific point mutation in LZTR1 enhance RAS-MAPK signaling? | Point-mutation knock-in of the Noonan syndrome variant |
| Does overexpression of a positive regulator amplify Ras signaling? | Doxycycline-inducible overexpression of the candidate gene |
| Does a tagged regulator localize to the membrane with Ras? | Tagged knock-in with fluorescent or epitope tag |
| Does a feedback mediator sustain RAS activation? | Knockout of RASH3D19 or equivalent feedback gene |
| Does a metabolic enzyme modulate Ras-driven immune evasion? | Knockout of glycosphingolipid synthesis genes in KRAS-mutant tumor cells |
How to Study the positive regulation of Ras protein signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RAS-GTP pulldown | Amount of active, GTP-bound Ras | Confirming positive regulation after gene perturbation |
| Phospho-ERK immunoblot | Activation status of the MAPK cascade | Routine readout of Ras pathway output |
| RNA sequencing | Transcriptional changes downstream of Ras | Identifying pathway signatures and immune evasion programs |
| CRISPR knockout screen | Genes whose loss alters Ras pathway activity | Discovery of novel positive regulators |
| Proximity labeling | Protein-protein interactions near Ras | Mapping the Ras interactome at the membrane |
| Live-cell imaging | Membrane localization and dynamics of Ras | Visualizing positive regulation in real time |
| Phosphoproteomics | Global phosphorylation changes | Mapping signaling networks downstream of Ras |
| Metabolomics | Metabolic rewiring in Ras-driven cells | Linking Ras signaling to lipid and amino acid metabolism |
Phospho-ERK and RAS-GTP assays
The most direct way to measure positive regulation of Ras signal transduction is to quantify active Ras and its downstream readouts. RAS-GTP pulldown assays using the Ras-binding domain of RAF1 capture the active fraction, while phospho-ERK1/2 immunoblotting reports pathway output. These assays are typically performed after serum starvation and stimulation to capture dynamic changes in pathway activity.
Transcriptomic profiling of Ras pathway output
RNA sequencing can identify transcriptional signatures associated with increased Ras signaling, including immediate early genes and metabolic targets. In KRAS-mutant models, transcriptomic profiling has revealed immune evasion programs and autophagy-related gene expression changes. Comparing knockout and wild-type cells provides a systems-level view of how a candidate positive regulator reshapes the transcriptome.
Functional genomics and CRISPR screens
Pooled CRISPR knockout screens are powerful for identifying genes whose loss reduces or increases Ras pathway activity. Such screens have been used to uncover regulators of RAS ubiquitination and signaling, including LZTR1. Secondary validation with individual knockouts and phospho-ERK readouts confirms screen hits. This approach is particularly useful for annotating genes to GO:0046579.
Imaging and proximity-based assays
Fluorescence microscopy and proximity labeling can visualize the spatial organization of Ras signaling at the plasma membrane. Tagged knock-in of Ras or its regulators allows tracking of membrane localization and co-clustering with effectors. These methods complement biochemical assays by revealing where and when positive regulation occurs within the cell.
How CRISPR Can Be Used to Study GO:0046579 positive regulation of Ras protein signal transduction
Knockout
CRISPR knockout is used to delete candidate positive regulators and measure the resulting change in Ras pathway activity. For example, knockout of LZTR1 increases RAS-MAPK signaling, confirming its role as a negative regulator whose loss enhances positive regulation. Knockout of KRAS itself abolishes pathway output and serves as a control. Pooled knockout screens can interrogate hundreds of candidates simultaneously.
Point Mutation
Point-mutation knock-in is essential for modeling disease-associated variants such as Noonan syndrome-causing LZTR1 mutations that specifically affect the Kelch domain substrate-recognition surface. CRISPR base editing or homology-directed repair can introduce these precise changes, allowing researchers to test whether a specific amino acid substitution enhances RAS-MAPK signaling. This approach distinguishes gain-of-function from loss-of-function mechanisms.
Knock-in
Knock-in of tags or reporters enables visualization and quantification of positive regulation. Fluorescent or epitope tags can be inserted at endogenous loci to track Ras or its regulators without overexpression artifacts. Knock-in of inducible promoters allows controlled expression of candidate genes to test dose-dependent effects on Ras signaling.
Overexpression
Overexpression models are used to test whether increasing the abundance of a candidate gene is sufficient to activate Ras signaling. Inducible overexpression of RASH3D19 or similar feedback mediators can sustain RAS activation in KRAS-mutant cancer cells. Overexpression of wild-type or mutant LZTR1 can reveal dominant effects on pathway activity. These models complement knockout studies by testing sufficiency rather than necessity.
How EDITGENE Supports positive regulation of Ras protein signal transduction Research
Researchers studying positive regulation of Ras protein signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway activation or whether its annotation reflects a correlative association. Establishing causality requires precise genetic perturbation, ideally at the endogenous locus, combined with quantitative readouts of Ras pathway activity such as RAS-GTP levels and phospho-ERK. EDITGENE provides the cell model engineering and screening services needed to move from candidate gene lists to validated mechanisms.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of Ras protein signal transduction research.
Frequently Asked Questions About positive regulation of Ras protein signal transduction
What is GO:0046579?
GO:0046579 is the Gene Ontology biological process term for positive regulation of Ras protein signal transduction, defined as any process that activates or increases the frequency, rate or extent of Ras protein signal transduction.
What genes are involved in positive regulation of Ras protein signal transduction?
Key genes include KRAS, LZTR1, SOS1, GRB2, SHC1, RAF1, MAP2K1, MAPK1, PIK3CA, AKT1, NFE2L2, SQSTM1, USP13, RASH3D19, UBA1, CUL3, PTPN11 and NF1, based on published functional studies.
How is positive regulation of Ras signaling measured experimentally?
Common methods include RAS-GTP pulldown assays, phospho-ERK immunoblotting, RNA sequencing and CRISPR screens, as described in the literature.
What diseases are linked to increased Ras signaling?
Increased Ras signaling is linked to KRAS-driven cancers, Noonan syndrome and other RASopathies, and has been implicated in inflammatory conditions such as rheumatoid arthritis.
What is the role of LZTR1 in Ras signaling?
LZTR1 regulates RAS ubiquitination and signaling; loss-of-function mutations enhance RAS-MAPK signaling and cause Noonan syndrome.
Can CRISPR be used to study positive regulation of Ras signaling?
Yes, CRISPR knockout, point-mutation knock-in, knock-in tagging and overexpression models are all used to perturb candidate regulators and measure changes in Ras pathway activity.
What is the relationship between KRAS mutations and positive regulation of Ras signaling?
KRAS mutations lock the protein in an active state, which is a direct form of positive regulation; co-occurring mutations further shape pathway output.
How does glycosphingolipid synthesis relate to Ras signaling?
Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer, linking lipid metabolism to positive regulation of Ras signaling.
What is the role of USP13 in KRAS signaling?
USP13 facilitates a ferroptosis-to-autophagy switch by activating the NFE2L2/NRF2-SQSTM1/p62-KEAP1 axis in a manner dependent on the KRAS signaling pathway.
What model systems are used to study positive regulation of Ras signaling?
Common models include CRISPR knockout and knock-in cell lines, inducible overexpression systems, and patient-derived cells with disease-associated mutations.
Conclusion
GO:0046579, positive regulation of Ras protein signal transduction, is a central biological process that integrates receptor-proximal activation, nucleotide exchange, membrane anchoring, effector engagement and feedback amplification. Its dysregulation underlies major human diseases, from KRAS-driven cancers to Noonan syndrome, and it is a frequent target of functional genomics screens. Understanding which genes positively regulate Ras signaling, and how, requires precise genetic models and quantitative pathway readouts. By combining CRISPR knockout, point-mutation knock-in, tagged knock-in, overexpression and library screening with bioinformatics, researchers can systematically annotate and validate the regulators that shape Ras pathway output. This integrated approach is essential for translating pathway knowledge into therapeutic strategies.
References
- 1. Soula M et al.. 2024. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer.. Nature 633(8029):451-458 PMID: 39112706
- 2. Bigenzahn JW et al.. 2018. LZTR1 is a regulator of RAS ubiquitination and signaling.. Science 362(6419):1171-1177 PMID: 30442766
- 3. Mondal K et al.. 2024. KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.. Cells 13(14) PMID: 39056802
- 4. Motta M et al.. 2019. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.. Hum Mol Genet 28(6):1007-1022 PMID: 30481304
- 5. Wang X et al.. 2025. Ginseng exosomal miRNA ameliorates rheumatoid arthritis by mediating KRAS-MAPK signaling.. Int Immunopharmacol 161:115046 PMID: 40517734
- 6. Chen L et al.. 2025. USP13 facilitates a ferroptosis-to-autophagy switch by activation of the NFE2L2/NRF2-SQSTM1/p62-KEAP1 axis dependent on the KRAS signaling pathway.. Autophagy 21(3):565-582 PMID: 39360581
- 7. Treekitkarnmongkol W et al.. 2026. RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer.. Nat Cell Biol 28(1):197-206 PMID: 41326795
- 8. Shern JF et al.. 2014. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.. Cancer Discov 4(2):216-31 PMID: 24436047
